Cardiovascular diseases

Our strategic planning of therapeutic areas for development of new and generic drugs, as well as cellular products is based on the in-depth analysis of the patient population needs in the Russian Federation for various medical products and treatments. Currently, we are pursuing research and development of therapies for the following diseases and pathological conditions.

Cardiovascular diseases, thrombosis and embolism.

Thrombosis and embolism are the main causes of death in developed countries, causing cerebral strokes and heart attacks.

A variety of drugs available on the market that can dissolve the blood clots. However, all the thrombolytic drugs that are currently on the market, have a number of drawbacks. They should be administered in a very short time (preferably in the first 1-2 hours) after the onset of the symptoms of stroke or heart attack. In addition, a powerful thrombolytic effect of such medications can trigger the development of bleeding in patients, which may significantly complicate their condition and even cause death.

Our compamy have several innovative medical products in the pipeline that can provide a safe and effective treatment of thrombosis and embolism. Our product Reveliza® (alteplase®) possess a pronounced thrombolytic effect and is in the preclinical development right now.

Our products:

GNR-004 Protein based Biosimilar Phase III clinical studies